Data from MHRA (Medicines and Healthcare products Regulatory Agency, UK) - Curated by EPG Health - Last updated 01 March 2018


DDAVP®/Desmopressin Intranasal Solution is indicated for:

1) The diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus.
2) The treatment of nocturia associated with multiple sclerosis where other treatments have failed.
3) Establishing renal concentration capacity.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Load more

Related Content

More information

Category Value
Authorisation number PL 03194/0001R
Orphan designation No
Date First Approved 28-04-1997
Type Medicinal product subject to medical prescription
Marketing authorisation holder Ferring Pharmaceuticals Ltd